As mentioned above, ICAS-O often requires intraarterial or intravenous GP IIb/IIIa inhibitor infusion, emergent balloon angioplasty, and stenting (11, 15–17, 29). This evidence concerns the gene ITGA2B and familial isolated congenital asplenia.